We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cambridge Cognition Holdings Plc | LSE:COG | London | Ordinary Share | GB00B8DV9647 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 52.00 | 51.00 | 53.00 | 52.00 | 52.00 | 52.00 | 49,034 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 12.61M | -409k | -0.0117 | -44.44 | 18.12M |
TIDMCOG
RNS Number : 4114B
Cambridge Cognition Holdings PLC
10 January 2018
Cambridge Cognition Holdings Plc
('Cambridge Cognition' or the 'Company')
Trading update and notice of results
Cambridge Cognition Holdings plc, (AIM: COG), the specialist developer of computerised tests for detection and monitoring of neuropsychological disorders, announces a trading update for the year ending 31 December 2017.
The number of Pharmaceutical Clinical Trials and Academic Research contracts secured in the year, now combined in a single product group, has increased by 18% when compared to the prior year. This reflects the sales strategy implemented at the start of the year to focus on securing smaller earlier staged studies to build a strong pipeline of sales opportunities for future years. The Company continues to grow its Services revenue as outlined in the interim results to improve the overall revenue mix.
The Company had expected to sign two large contracts with a combined value of approximately GBP2.3m in the last quarter of the year, and whilst the contracts are at an advanced stage, they are now expected to commence in the first half of 2018. Consequently, revenue for the full year to 31 December 2017 is expected to be marginally below the GBP6.9m reported in 2016 with the sales order pipeline value as at 1 January 2018 up 56% on the prior year. The Company now expects to be broadly break even for the year at the EBITDA line (before share based payment charges).
Cash balances at year end are expected to be approximately GBP1.9m (2016: GBP2.4m), which provides sufficient financial resources to implement the next phase of the Company's strategic plan.
The preliminary results for the year ended 31 December 2017 will be released on 22(nd) March 2018.
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.
Enquiries
Cambridge Cognition Holdings PLC Steven Powell, Chief Executive Tel: 01223 810 Officer 700 Nick Walters, Chief Financial press@camcog.com Officer finnCap Ltd (NOMAD and Joint Broker) Tel: 020 7220 0500 Geoff Nash / Simon Hicks (Corporate Finance) Alice Lane (Corporate Broking) Dowgate Capital Stockbrokers Limited Tel: 020 3903 (Joint Broker) 7715 David Poutney/ James Serjeant (Corporate Broking) IFC Advisory Limited (Financial Tel: 020 3053 PR and IR) 8671 Tim Metcalfe/ Graham Herring
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTDKLFBVFFBBBD
(END) Dow Jones Newswires
January 10, 2018 02:00 ET (07:00 GMT)
1 Year Cambridge Cognition Chart |
1 Month Cambridge Cognition Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions